New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.
Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial. Journal of renal nutrition Chertow, G. M., DILLON, M. A., Amin, N., Burke, S. K. 2000; 10 (3): 125-132Abstract
To determine the effects of sevelamer hydrochloride on serum phosphorus, calcium, calcium x phosphate product, and parathyroid hormone (PTH) in patients treated with and without vitamin D metabolites and calcium supplementation.Long-term, open-label clinical trial.Hemodialysis units.One hundred ninety-two adult patients with end-stage renal disease on hemodialysis.An extended treatment period of sevelamer hydrochloride, preceded and followed by phosphate binder washout periods.Treatment-related changes in serum phosphorus, calcium, calcium x phosphate product, and PTH.Subjects treated with sevelamer alone, sevelamer with vitamin D metabolites (with or without calcium), and sevelamer with calcium without vitamin D experienced significant reductions in mean serum phosphorus (range, 2.1 to -2.9 mg/dL) and the calcium x phosphate product (range, -16.3 to -23.4 mg2/dL2). The mean serum calcium concentration increased in all subgroups except those treated with sevelamer alone (range, +0.3 to +0.5 mg/dL). In contrast, only subjects treated concurrently with vitamin D metabolites experienced a reduction in PTH. Subjects treated with sevelamer alone or sevelamer with calcium without vitamin D experienced an increase in PTH with treatment.Sevelamer hydrochloride is a safe and effective phosphate binder in hemodialysis patients. Sevelamer should be used in combination with vitamin D metabolites to jointly control hyperphosphatemia and hyperparathyroidism. Randomized clinical trials will be required to determine the optimal management strategies for metabolic bone disease in end-stage renal disease, as well as less advanced stages of chronic renal insufficiency.
View details for PubMedID 10921533